The problem
Over 50% of patients are nauseous on GLP-1 injections, and needles for life are unsustainable.
Despite GLP-1s proven benefits, many patients churn due to side effects or painful delivery.
Our platform
A convenient nasal spray delivering the same drug with similar efficacy.
Our underlying nanoparticle technology can also expand to a broader class of peptides and other biologics in the future for respiratory or neurological use cases.
Our opportunity
A massive market exceeding $100B+ in a few years.
Besides nausea, the nose-to-brain (N2B) delivery also enables new neurological indications such as addiction or dementia that are being explored for GLP-1s.
Robin Guo
CEO & Co-Founder
Professor Kam Leong
Inventor & Co-Founder
Dr. Huiyi Liang
Lead Scientist
Professor Edward X. Guo
Scientific Advisor
